Ir para o conteúdo principal

Mink Therapeutics (NASDAQ: INKT) — Perfil da empresa, notícias e dados financeiros

Logo de Mink Therapeutics
INKT Mink Therapeutics
Mink Therapeutics primary media
Perfil da empresa

Mink Therapeutics

Mink Therapeutics (NASDAQ:INKT) specializes in developing innovative therapies aimed at transforming the treatment landscape for patients facing serious diseases. With a focus on utilizing cutting-edge research and technology, Mink is dedicated to advancing a diverse portfolio of therapeutic candidates through clinical development. Their projects span a range of therapeutic areas, including oncology, autoimmune disorders, and infectious diseases. Mink's objective is to bring novel treatments from the bench to the bedside, addressing unmet medical needs and improving patient outcomes. The company's operations are fueled by a commitment to excellence in research and development, with an emphasis on collaboration and innovation to achieve breakthroughs in medicine.

Resumo

Public USParticipação acionária
2017Ano de fundação
31Funcionários
New York, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
New York City, US

Produtos e/ou serviços de Mink Therapeutics

  • Development of novel immunotherapies targeting hard-to-treat cancers using proprietary technology.
  • Collaboration on a gene editing platform to enhance the efficacy of cancer treatments.
  • Research into personalized cancer vaccines leveraging patient-specific tumor neoantigens.
  • Advanced diagnostics services for early detection of oncological diseases.
  • Partnership in creating monoclonal antibodies for immune system modulation in cancer therapy.
  • Investment in AI-driven platforms for optimizing drug development processes.

equipe executiva do Mink Therapeutics

  • Garo H. ArmenExecutive Chairman
  • Jennifer S. BuellCo-Founder, President, CEO & Director
  • Melissa OrilallPrincipal Financial Officer
  • Austin CharettePrincipal Accounting Officer
  • Terese C. HammondHead of Inflammatory & Pulmonary Diseases
  • Marco PurbhooHead of Translational Medicine

Principais indicadores financeiros

Resultados divulgados pela Mink Therapeutics, em USD.

Cap. de mercado
55,1 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-2.4
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Mink Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-12,5 mi-12,5 mi
0-10,7 mi-10,8 mi
0-22,9 mi-22,5 mi
2,7 bi-30,9 mi-28 mi